KM-023 / Kamari Pharma - LARVOL DELTA

TRPV3 novel inhibitor KM-023 as a potential oral treatment for keratodermas (SID 2025) - "The results suggest that KM-023 can be potentially used to treat OS, PC and other Keratodermas. A Phase 1 study in healthy volunteers and OS patients is planned to be initiated shortly."

Dermatology • Inflammation • Pruritus • LORICRIN • TRPV3

Kamari Pharma Announces Abstracts Accepted for Presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (GlobeNewswire) - "Kamari Pharma...announced two abstracts reporting results for its novel TRPV3 inhibitors, KM-001(topical) and KM-023 (oral), have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.....Late breaking poster presentation includes Phase 1b clinical trial results demonstrating the safety and preliminary efficacy of KM-001, a topical TRPV3 inhibitor, for the treatment of palmoplantar keratoderma. Oral presentation highlights favorable in vitro and in vivo safety and efficacy data of novel TRPV3 inhibitors KM-001(topical) and KM-023 (oral) in preclinical 3D skin and mouse models."

Late-breaking abstract • P1 data • Preclinical • Dermatology